DSCSA Compliance Under Regulatory Freeze: What Wholesale Distributors Need to Know in 2025

On January 20, 2025, the Trump administration issued a broad regulatory freeze affecting pending federal rules and enforcement actions. The Drug Supply Chain Security Act (DSCSA) Enhanced Drug Distribution Security requirements — set to take full effect November 27, 2025 — fall under this freeze. Wholesale drug distributors now face uncertainty about whether FDA enforcement of the DSCSA serialization and interoperability deadlines will proceed as planned.

Regulatory Background: DSCSA Enhanced Requirements

The Drug Supply Chain Security Act (Pub. L. 113-54, enacted November 27, 2013) established a phased timeline for creating an electronic, interoperable system to identify and trace prescription drugs distributed in the United States. The statute divided implementation into two phases:

Lot-level tracing (2015-2023): Trading partners exchanged transaction history, transaction information, and transaction statements using paper or electronic systems. This phase ended November 27, 2023.

Unit-level serialization (2023-2025): All prescription drug packages must carry a unique product identifier (serialized barcode). Trading partners must verify product identifiers, store serialized transaction data in interoperable electronic systems, and respond to verification requests. Full enforcement for wholesale drug distributors begins November 27, 2025.

Under 21 CFR Part 582, wholesale drug distributors must:

• Verify product identifiers on saleable returns before redistribution (§582.31)
• Investigate and resolve verification exceptions within 5 business days (§582.33)
• Maintain an interoperable electronic system capable of ATP (Authorized Trading Partner) verification and EPCIS (Electronic Product Code Information Services) data exchange (§582.35)
• Quarantine product with suspect or illegitimate identifiers and notify FDA within 24 hours (§582.37)

The Regulatory Freeze Order

The January 20, 2025 memorandum from the Office of Management and Budget directed federal agencies to:

1. Immediately withdraw all rules that have been sent to the Office of the Federal Register but not yet published
2. Postpone effective dates for rules published but not yet in effect by 60 days
3. Suspend enforcement of recently implemented rules pending review by agency heads appointed by the new administration

The FDA has not issued public guidance clarifying whether the November 27, 2025 DSCSA deadline is subject to the freeze. Unlike rules subject to notice-and-comment rulemaking under the Administrative Procedure Act, the DSCSA timeline is statutory — enacted by Congress in the law itself. The FDA's implementing regulations (21 CFR Part 582) were finalized in 2019 and have been in effect for six years.

However, enforcement discretion — FDA's decision about when and how to pursue compliance actions — falls within the agency's administrative authority and could be affected by the freeze.

What Changed (And What Did Not)

Unchanged: The statutory deadline of November 27, 2025 remains in the U.S. Code. Congress, not the executive branch, would need to amend or delay it.

Unchanged: The requirements in 21 CFR Part 582 remain effective regulation. Distributors are still legally obligated to comply.

Uncertain: Whether FDA will exercise enforcement discretion to delay inspections, warning letters, or other compliance actions targeting distributors not ready for full serialization by November 27, 2025.

Uncertain: Whether FDA will issue formal guidance extending timelines or offering safe harbor provisions for distributors making "good faith efforts" toward compliance.

As of February 2025, FDA has not published updated guidance on DSCSA enforcement priorities under the new administration.

Impact on Wholesale Drug Distributors

The regulatory freeze creates three operational risks for wholesale distributors approaching the November 2025 deadline:

1. Compliance investment uncertainty: Distributors investing in EPCIS-capable systems, VRS (Verification Router Service) integrations, and staff training face unclear ROI timelines. If FDA delays enforcement by 12-24 months, capital expenditures scheduled for Q2-Q3 2025 may be premature. However, waiting assumes a delay will be granted — a gamble if FDA proceeds with enforcement as planned.

2. Trading partner readiness gaps: Even if FDA delays enforcement for distributors, manufacturers and dispensers still face the same November 27, 2025 deadline. Distributors must be ready to exchange serialized data with upstream and downstream partners regardless of FDA's enforcement posture. A distributor unable to receive EPCIS messages from manufacturers will lose access to product from compliant suppliers.

3. State-level enforcement: Twenty-three states have adopted their own pedigree or track-and-trace requirements, some stricter than federal DSCSA standards. California's pedigree law (Business & Professions Code §4034) was preempted by DSCSA in 2015, but state boards of pharmacy retain authority to investigate and discipline wholesale distributors for failing to maintain adequate records. A federal enforcement delay does not prevent state action.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain logistics providers across 51 jurisdictions. The average compliance score in the directory is 51/100 — placing the typical entity in the "Fair" tier. This score reflects verified signals across state licensure, NABP accreditation, FDA registration, recall history, warning letters, and enforcement actions. It does not yet include DSCSA-specific compliance indicators, as FDA has not published a searchable database of entities that have completed VRS integration or ATP verification system implementation.

Of the 1,275 entities tracked, 1,234 hold active FDA establishment registration — a baseline requirement under 21 CFR Part 207 for any entity engaged in the manufacture, repackage, relabel, or salvage of drugs. However, FDA registration does not indicate DSCSA serialization readiness. An entity can be FDA-registered and still lack the interoperable electronic systems required under 21 CFR Part 582.

Only 63 entities in the directory hold NABP accreditation (formerly VAWD). NABP's accreditation criteria include review of facility security, personnel qualifications, and standard operating procedures — but the accreditation survey does not yet include a dedicated DSCSA technology audit. As of February 2025, NABP has not published whether its accreditation standards will be updated to include verification of EPCIS capability before the November 27, 2025 deadline.

The compliance score distribution shows significant variance in regulatory posture:

• 28 entities (2.2%) score in the "Excellent" range (76-100 pts)
• 281 entities (22.0%) score "Good" (61-75 pts)
• 919 entities (72.1%) score "Fair" (41-60 pts)
• 38 entities (3.0%) score "Poor" (21-40 pts)
• 9 entities (0.7%) score "Minimal" (0-20 pts)

Entities in the "Fair" tier typically hold active state licenses and FDA registration but lack NABP accreditation and have no public compliance signals beyond baseline requirements. These entities may face higher risk if FDA proceeds with DSCSA enforcement without delay, as their regulatory compliance track record provides no buffer against scrutiny.

What to Do Now

For QA managers and compliance officers navigating regulatory freeze uncertainty:

• Verify trading partner compliance baselines: Use the ColdChainCheck directory to confirm that upstream and downstream partners hold active state wholesale drug distributor licenses and FDA registration. Entities with expired licenses or suspended registration status should be flagged for immediate review, regardless of DSCSA timeline uncertainty.

• Document system readiness, not just compliance intent: If your organization has implemented EPCIS-capable systems, VRS integration, or ATP verification protocols, document completion dates and retain vendor contracts. In the event of FDA inspection — freeze or no freeze — evidence of operational capability carries more weight than a project roadmap. ColdChainCheck cannot verify your internal DSCSA readiness, but state boards of pharmacy may request this documentation during routine inspections.

• Monitor state-level enforcement separately: Check your state board of pharmacy website for any guidance on DSCSA enforcement during the federal freeze. States with independent pedigree or track-and-trace statutes (California, Florida, Nevada) may proceed with enforcement regardless of FDA posture. Cross-reference your state licenses in the ColdChainCheck directory to confirm all jurisdictions where you operate remain current.

• Track FDA guidance updates: ColdChainCheck will publish updates to the DSCSA compliance checklist if FDA issues formal enforcement discretion guidance or extends the November 27, 2025 deadline. Until then, assume the statutory deadline remains in effect and plan accordingly.

The regulatory freeze introduces timeline uncertainty, but it does not eliminate the compliance obligation. Entities waiting for explicit confirmation of a delay risk operational disruption if FDA enforcement proceeds as scheduled. The more prudent approach: continue implementation and use any granted extension as buffer time, not a substitute for readiness.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult with qualified legal counsel and verify all compliance requirements with the FDA and relevant state boards of pharmacy.